Gilead's hepatitis C drug Sovaldi gets off to strong start

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Total prescriptions (TRx) for Gilead's (GILD +1.3%) hepatitis C pill Sovaldi rose almost 70% to 1,764 in the week ended January 10, although it's worth pointing out that previous weeks included the holidays.

"Still, the Solvadi scripts to date are impressive and point to early, strong demand for the new Hep C pill," says Adam Feuerstein.

ISI analyst Mark Schoenebaum says: "If TRx were to only remain flat through year end and we assume 20% discounting on price and a similar capture rate to [Vertex Pharma's (VRTX)] Incivek for sales...we estimate that FY 2014 sales could be ~$2.4 B."